Purchase order NNX17CL73PLIGNAMED, LLC
Overview
Award facts
- Net obligations
- $125K
- $125,000of $125K potential value
- Period of performance
- Jun 9, 2017 to Dec 8, 2017
- Ended
- Modifications
- 0
- Latest action Jun 6, 2017
- Contract type
- Purchase order
- PIID NNX17CL73P
Description of requirement
IGF::OT::IGF LIGNAMED, LLC IS A DRUG DEVELOPMENT COMPANY WITH A FAST TRACK STRATEGY TO APPROVAL OF LGM2605, AN ORAL SMALL MOLECULE FOR USE AS A RADIATION MITIGATING AGENT THAT REDUCES HARMFUL EFFECTS OF RADIATION EXPOSURE OF NORMAL TISSUES. LIGNAMED AIMS TO EVALUATE LGM2605 AS A MITIGATOR OF SPACE-RADIATION INDUCED VASCULAR DAMAGE. NASA MISSIONS TO MARS WILL EXPOSE ASTRONAUTS TO SOLAR AND GALACTIC COSMIC MIXED RADIATION INCLUDING LOW DOSE. AND PROTON RADIATION, BUT DATA IS LACKING ON THE BIOLOGICAL AND PHYSIOLOGICAL EFFECTS IN HUMANS OF THIS MIXED SOURCE RADIATION. RESEARCH ON SPACE RADIATION EFFECTS ON CELLULAR SYSTEMS, MOLECULAR TARGETS AND ULTIMATELY ORGAN SYSTEMS HAS IDENTIFIED POTENTIAL HARMFUL SHORT AND LONG-TERM EFFECTS ON THE HEALTH OF ASTRONAUTS. WORK AT THE UNIVERSITY OF PENNSYLVANIA IDENTIFIED DAMAGE TO LUNGS YEARS AFTER A SINGLE EXPOSURE TO LOW-DOSE GAMMA, 56FE, 28SI AND PROTON RADIATION EXPOSURE IN MICE. ACUTE AND CHRONIC RADIATION EFFECTS IN ORGANS ARE CLOSELY ASSOCIATED WITH VASCULAR DAMAGE AND DYSFUNCTION. MULTIPLE STUDIES HAVE CONFIRMED SINGLE SOURCE RADIATION SIDE EFFECTS ASSOCIATED WITH SIGNIFICANT LOSS OF VASCULAR INTEGRITY: INCREASED VASCULAR LEAKINESS (EDEMA), AN ACTIVATED INFLAMMATORY PHENOTYPE AND EXTENSIVE OXIDATIVE DAMAGE. HOWEVER, DAMAGE TO THE VASCULAR NETWORK UNDER MULTIPLE RADIATION TYPES SIMULTANEOUSLY IS NOT UNDERSTOOD. LIGNAMED WILL EMPLOY GENE KNOCKOUT TECHNOLOGY IN VASCULAR MODELS EXPOSED TO SPACE-RELEVANT MIXED RADIATION REGIMENS TO INVESTIGATE THE INJURY TO THE VASCULATURE. WE HYPOTHESIZE THAT LGM2605 WILL MITIGATE SPACE RADIATION-INDUCED VASCULAR DAMAGE BY INHIBITING EARLY EVENTS THAT CAUSE INFLAMMATION. THIS STUDY WILL CONFIRM THAT 1) SPACE RADIATION DRIVES ENDOVASCULAR DAMAGE VIA ACTIVATION OF THE ENDOTHELIAL INFLAMMATORY PHENOTYPE RESULTING IN INCREASED PERMEABILITY AND 2) WILL VALIDATE LGM2605 AS AN EFFECTIVE MITIGATOR OF SPACE RADIATION-INDUCED VASCULAR DAMAGE BY INHIBITING EARLY EVENTS THAT DRIVE LONG TERM ADVERSE SEQUELLAE.
Dates and value
- Award date
- Signed on Jun 6, 2017
- Potential end of performance
- Dec 7, 2017
- Current value
- $125,000Base and exercised options
- Potential value (if all options are exercised)
- $125,000
Obligations by fiscal year of action
- FY2017: $125,000
Total across 1 fiscal year: $125,000
Source: Federal Procurement Data System contract actions as published by SAM.gov and USAspending.gov; latest action recorded Jun 6, 2017. View on USAspending · Recipient on SAM.gov
Recipient
Business types and certifications
As represented in SAM.gov at the time of the action.
Subcontracting network
The prime, the subcontractors on this award, and their own subcontractors.
Agency and place
Awarding and funding
- Awarded by
- National Aeronautics and Space Administration
- NASA SHARED SERVICES CENTER
- Funded by
- National Aeronautics and Space Administration
- NASA SHARED SERVICES CENTER
- Funded from
- Space technology (DIRECT)Program activities080-0131Federal accounts (agency financial reports)
Place of performance
- Place of performance
- Philadelphia, Pennsylvania 19104-2853
- Congressional district (place of performance)
- PA-03As reported at the time of the action
Classification and competition
Classification
- Product or service (PSC)
- AR11R&D- SPACE: AERONAUTICS/SPACE TECHNOLOGY (BASIC RESEARCH) (research and development)
Competition
- Extent competed
- Full and open competition after exclusion of sourcesD
- Solicitation procedures
- Negotiated proposal/quoteNP
- Set-aside
- Small business set aside - totalSBA
- Contract pricing
- Firm fixed priceJ
- Offers received
- 500
Contract details
- Subcontracting plan
- Plan not requiredB
- Major program
- LGM2605 as a mitigator of space radiation-induced vascular damage
- Service Contract Act labor standards
- No
- Commercial procedures
- Commercial item procedures not usedD
- Government-furnished property
- Transaction does not use GFE/GFPN
- Bundled requirement
- Not bundledH
- Consolidated requirement
- Not consolidatedD
- Undefinitized action (terms not final)
- No
- Performance-based service acquisition
- No - service where PBA is not used.N
Linked notices
Notice | Notice ID | Type | Link | Posted |
|---|---|---|---|---|
Transaction history
Modification history
- Base award
- Jun 6, 2017Base obligation at award: $125,000
- Latest action
- Jun 6, 2017 — Base awardModification 0; obligation change +$125,000
- Actions by type
- Base award1
Similar awards
PIID | Match | Awardee |
|---|---|---|
All contract data
All contract data
Every other field reported for this award, as of its latest reported action
Competition
- Evaluation preference
- No preference used
- Local area set-aside
- No
- Simplified procedures for commercial items
- No
- A-76 (FAIR Act) action
- No
Pricing and financing
- Paid by purchase card
- No
- Latest action: change in base and exercised options
- $125,000
- Latest action: change in base and all options
- $125,000
Socio-economic and policy
- Recovered materials and sustainability
- No clauses included and no sustainability includedC
- EPA-designated product
- Not requiredE
- Clinger-Cohen Act planning (IT)
- No
- Research program (SBIR/STTR)
- Small business innovation research program phase i actionSR1
- Walsh-Healey Act (materials and supplies)
- No
- Construction wage rates (Davis-Bacon)
- No
Place and origin
- Domestic or foreign entity
- U.S. owned businessA
- Country of product or service origin
- United statesUSA
- Place of manufacture
- Not a manufactured end productC
Structure
- Award or IDV
- Award
- Award type
- Purchase orderB
- Awarding agency code
- 8000
- Awarding sub-tier code
- 8000
- Contracting office code
- 80NSSC
- Transactions recorded under this award key
- 1
Funding
- Funding agency code
- 8000
- Funding sub-tier code
- 8000
- Funding office code
- 80NSSC
- Treasury accounts
- 080-2017/2018-0131-000
- Object classes
- 25.5: Research and development contracts